🧨 Factors associated w/ Pulmonary Embolism in ORAL surveillance: ⚡️history of VTE ⚡️antidepressant use ⚡️BMI≥30 ⚡️corticosteroid use ⚡️male gender ⚡️age ≥65 ⚡️Hx of Hypertension ⚡️hormonal ttmt use POS0239 #EULAR2022 @RheumNow https://t.co/pT6MDAUbjH

Prof van Lear reviews #EULAR ’s 11 points to consider for difficult to treat RA (D2T RA) published here https://t.co/zOLiMChjx8 #EULAR2022 @rheumnow (1/n) https://t.co/mVjJ5A1VkW

• EULAR points to consider for the management of difficult-to-treat rheumatoid ar…

Dr. E. Loza reminds #EULAR2022 that it is important to measure response of patients when using clinical guidelines for treatment! It will help us adapt guidelines for the future to help patients. @RheumNow https://t.co/pMkpsMH44U

The reference is at https://t.co/Auwrimc0jt

• Difficult-to-treat rheumatoid arthritis: contributing factors and burden of dis…

Eun et al. South Korean population based study. n=138,592 RA patients. aHR dementia 1.19 (95%CI 1.16–1.23), Alzheimers 1.21 (95%CI 1.67-1.25), Vascular dementia 1.10 (95%CI 0.99-1.21) @RheumNow #EULAR2022 OP0271 https://t.co/URNYnYzuF6

• EULAR Abstract Archive

Razmjou et al. Survival in RA-ILD patients with lung transplant comparable to other cohorts. Not surprisingly UIP pattern trended to worse outcome HR 7.13, p=0.06 @RheumNow #EULAR2022 OP0275 https://t.co/RJ1nMkHwRh https://t.co/iUENMhqiX3

• EULAR Abstract Archive

Case reports of tofacitinib efficacy for calcinosis over last couple of years. Benefits were relatively quickly (within 3m) reported by Jiri Vencovsky #eular2022

Lisa Rider suggests that calcinosis is more commonly seen in JDM than adults maybe the result of the more prominent vasculopathy and IFN signature. #EULAR2022

Always satisfying to see the big plenary hall in full flight #EULAR2022 @RheumNow https://t.co/DkzZCFvFw7

SLE trials update Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases. https://t.co/xmYbgOplsm https://t.co/QUrtwAJqNl

• https://bit.ly/3NVbUHX

Jacob van Laar on difficult to treat (D2T) RA. Comorbidities, fibromyalgia, obesity contribute to this. Associated with pauci-immune synovial pathotype. A consensus definition of D2T developed and est 5-20% of RA meet this criteria #EULAR2022 @RheumNow https://t.co/MgxJIJgxYw

#EULAR2022 Difficult to treat RA (D2TRA): Synovial pathotype shows a pauci-immune phenotype, different from other forms of RA @RheumNow https://t.co/0osG5Bb5yb

#EULAR2022 Difficult to treat RA Which is the only independent risk factor in Netherlands study for D2TRA? @RheumNow

Those #EULAR2022 vaccination bracelets are not the most discrete of things (and you can’t take them off). https://t.co/02NrLcqzT2

POS0130 from #EULAR2022 found only a 50% concordance between PsO patients with self-reported MSK pain and US findings of PsA. Remember, not all pain in PsO is PsA. @RheumNow https://t.co/CiMUa9HNgk